

Nazareth (Belgium)/Rotterdam (The Netherlands), 13 January 2022 – 9:30AM CET

Fagron publishes 2022 ESG targets

Corporate social responsibility is at the heart of Fagron's operations and strategy. Fagron's products and services contribute every day to improving the health of people worldwide. Fagron strives to:

- reduce its impact on the environment;
- provide products that meet all relevant quality and safety standards;
- provide benefit to its people;
- take responsibility in the supply chain; and
- give back to the communities in which Fagron operates.

To give concrete expression to this aspiration, Fagron is publishing its ESG objectives for 2022.

In addition to the previously defined targets for reducing the greenhouse gas intensity of Fagron's operations, Fagron also sets itself the objective in its 2022 ESG plan, among others, to purchase 50% of its electricity from renewable sources by 2025 and to separate waste at all its locations. In terms of gender equality, Fagron aims not only to have a 50/50 gender distribution of all its staff, but by 2025 also at management level. Furthermore, Fagron wants at least 75% (in purchasing value) of its suppliers to have accepted the Fagron Business Partner Code of Conduct by 2025. The full 2022 ESG plan of Fagron, including all targets can be read on our [website](#).

Rafael Padilla, CEO of Fagron: *"Corporate social responsibility is at the heart of what we do: by personalizing medicine, they become accessible to even more people. In 2021 we presented our ESG strategy and reported extensively on our social responsibility for the first time in our 2020 annual report. Since then, we have made some important steps, such as a significant reduction in the greenhouse gas intensity of our operations (scope 1, 2 and business travel) and an increase in the number of annual performance and development reviews of our employees to 85%. However, we must continue to develop ourselves. Fagron is thus constantly adapting its ESG strategy in response to developments in the ESG field, trends in the sector and regions where we operate, and the input we receive from our stakeholders. I am proud that we have again set ourselves challenging targets for 2022 to make our contribution to a better world."*

Fagron endorses all 17 Sustainable Development Goals (SDGs) defined by the United Nations in 2015. Based on the defined sustainability strategy, Fagron has selected five categories where it actively focuses and where it believes it can make the highest contribution: environment, our people, supply chain responsibility, giving back and good governance.

Further information

Karen Berg
Global Investor Relations Manager
Tel. +31 6 53 44 91 99
karen.berg@fagron.com

Sanne Nusselder
Global ESG Manager
Tel.: +31 6 22 58 26 65
sanne.nusselder@fagron.com

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in 35 countries around the world.



Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. Fagron's operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.